SumZero recently featured our analysis on the multitude of issues facing Valeant Pharmaceuticals (VRX). In a “Fund Face Off,” our short analysis was pitted against the long analysis from Navi Hehar of Mile 26 Capital. Read the entire “Fund Face Off” here.
For more analysis on Valeant, see our reports here:
- Cutting Through Valeant’s Story – 6/30/14
- Danger Zone: Stocks With Most Misleading N0n-GAAP Earnings – 7/21/14
- The Dangers Of Non-GAAP Earnings – 11/17/15
- Danger Zone: Valeant Pharmaceuticals – 2/29/16